Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk,...
-
Upload
dorthy-goodwin -
Category
Documents
-
view
213 -
download
0
Transcript of Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk,...
![Page 1: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/1.jpg)
Exploration of Endpoints for Pivotal Clinical Trials to Treat
AUDRaye Z. Litten, Ph.D.
Daniel Falk, Ph.D. (Discussant)
Division of Treatment and Recovery ResearchNational Institute on Alcohol Abuse and Alcoholism
Presented at the Measures of Outcome for Stimulant Trials (MOST) meeting of the ACTTION Initiative
Rockville, MD, March 25, 2015
![Page 2: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/2.jpg)
Key Organizations
NIAAA• Dan Falk, Joanne Fertig, Megan Ryan
ACTIVE Group• FDA, EMA, pharmaceutical companies,
academic researchers, NIAAA, NIDA
![Page 3: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/3.jpg)
FDA Draft Guidance for Industry: Primary Alcohol Drinking Endpoints
Dichotomous Measures
• Percent Subjects Abstinent
• Percent Subjects with No Heavy Drinking Days (PSNHDD)
– Subjects with no heavy drinking days ÷ total number of subjects
– Heavy drinking day (HDD): 4 or more drinks/ drinking day for women and 5 or more drinks/drinking day for men
– PSNHDD includes abstinence and low-risk drinking
![Page 4: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/4.jpg)
What evidence was provided for consideration of PSNHDD as a
primary endpoint?
![Page 5: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/5.jpg)
Evidence of Clinical Benefit (PSNHDD)
• Alcohol Clinical Trials
• Treatment Settings
• Epidemiologic Studies
![Page 6: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/6.jpg)
• Alcohol Clinical Trials
• Treatment Settings
• Epidemiologic Studies
Evidence of Clinical Benefit (PSNHDD)
![Page 7: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/7.jpg)
COMBINE Trial
• Duration: 4 months treatment (1 year follow-up)
• Participants: alcohol dependent (n=1383)
• At Randomization: 3 to 21 days required abstinence
• Medications: naltrexone, acamprosate (alone and in combination)
• Behavioral therapies: – Medical Management (MM)
– Combined Behavioral Intervention (CBI)
Anton et al., JAMA 295: 2003-2017, 2006
![Page 8: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/8.jpg)
Drinker Inventory of Consequences (DRINC)
• 37-item alcohol-related consequences measure
• Four Subscales
– Physical (e.g., “I have been sick and vomited after drinking”)
– Social responsibility (e.g., “I have gotten into trouble because of drinking”)
– Interpersonal (e.g., “I have lost a friend because of my drinking”)
– Impulse control (e.g., “I have had an accident while drinking or intoxicated”)
Miller et al., Project MATCH Monograph Series, 1995
![Page 9: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/9.jpg)
Heavy Drinking increases DRINC Scores at Follow-Up
Treatment Months 3&4
Follow-up Month 2.5
Follow-up Month 9
Follow-up Month 12
0
5
10
15
20
25
30
2.55.4
7.9 7.8
13.7
17.920.5
18.6
No HDD (Months 3&4) HDD (Months 3&4)
DR
INC
Sco
re (
37-i
tem
) (M
ean
)
COMBINE Study
![Page 10: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/10.jpg)
0
5
10
15
20
25
Weeks 8-16 Week 26 Week 52 Week 68
2.44.9
7.3 6.6
2.9
6.7
9.410.6
13.7
17.920.5
18.6
Abstainers Low Risk HDD
Abstainers and Low Risk have similar DRINC Scores during Treatment and Follow-up
DR
INC
Sco
re (
37-i
tem
) (M
ean
)
COMBINE Study
Treatment Months 3-4
Follow-up Month 2.5
Follow-up Month 9
Follow-up Month 12
![Page 11: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/11.jpg)
Abstainers and Low Risk have similar Drinks/Drinking Day during Treatment and Follow-up
0
1
2
3
4
5
6
7
8
9
10
Weeks 8-16 Week 26 Week 52 Week 68
0
2.7
4.24.9
2.4
3.64.3
5.4
8.29.1
9.89.1
Abstainers Low Risk HDD
Dri
nks
per
Dri
nki
ng
Day
(M
ean
)
Treatment Months 3-4
Follow-up Month 2.5
Follow-up Month 12
Follow-up Month 9
![Page 12: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/12.jpg)
• Alcohol Clinical Trials
• Treatment Settings
• Epidemiologic Studies
Evidence of Clinical Benefit (PSNHDD)
![Page 13: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/13.jpg)
Kaiser Permanente Studies• Study Site:
• KP Chemical Dependency Recovery Program (CDRP) in Sacramento, California
• Participants:
• N = 995 adult patients (18+) with alcohol dependence/abuse
• Recruited from two randomized studies (Weisner et al., 2000, 2001)
• Predictor: Drinking Status (past 30 days) (6 months post-treatment)
• Abstinent• Low-Risk Drinker: drank but no heavy drinking days (5+ drinks/drinking day)• Heavy Drinker: 1+ heavy drinking days
• Outcomes: – Addiction Severity Index (12 months post-treatment)
• Medical• Psychiatric• Family/Social• Employment
– Treatment Cost & Utilization (up to 5 years post-treatment)
![Page 14: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/14.jpg)
Clinical Relevance of Abstinent, Low-Risk, and Heavy Drinking Post-Treatment
Outcomes
Compared with Abstinent Group:Low-Risk
Heavy Drinking
Drinking greater much greater
Consequences: psychiatric/family/social problems
similar higher
Treatment Utilization: inpatient/ED similar higher
Treatment Costs similar higherKline-Simons et al. ACER 37(Suppl):E373-E380, 2013 and ACER 38:579-586, 2014
![Page 15: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/15.jpg)
• Alcohol Clinical Trials
• Treatment Settings
• Epidemiologic Studies
Evidence of Clinical Benefit (PSNHDD)
![Page 16: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/16.jpg)
Epidemiologic Evidence: Clinical Benefit of PSNHDD
• National Alcohol Surveys
– Treated or concerned drinkers who restrict alcohol intake to low volume and did not have any heavy drinking days had a low risk of alcohol dependence or abuse (Greenfield, unpublished data)
• National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)
– Subjects with no heavy drinking days carried a much lower risk for alcohol dependence and AUD symptoms than those who experienced heavy drinking (Dawson et al. 2007)
![Page 17: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/17.jpg)
Summary
No heavy drinking vs heavy drinking• No heavy drinking decreases risk for relapse to heavy
drinking and dependence, consequences, treatment utilization and cost compared to heavy drinking
Abstinence vs low risk drinking vs heavy drinking• Relapse to heavy drinking and dependence: heavy
drinking>>low risk>abstinence• Consequences: heavy drinking> low risk=abstinence• Treatment utilization and cost: heavy drinking>low
risk=abstinenceN
![Page 18: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/18.jpg)
FDA Guidance: Clinical Benefit of PSNHDD
“Patients who never exceeded the heavy drinking limits had minimal alcohol-related consequences and were much less likely to have relapsed at follow-up.”
-- FDA Guidance Summary Statement
![Page 19: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/19.jpg)
Is PSNHDD a Sensitive Outcome in Detecting
Treatment Effects in Clinical Trials?
![Page 20: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/20.jpg)
PSNHDD a Sensitive Endpoint?
Not as sensitive as continuous outcome measures• Number of heavy drinking days outcome
was significant in five alcohol clinical trials• PSNHDD was significant in only two of the
trials
Examples: COMBINE (PSNHDD sensitive) and varenicline trials (PSNHDD less sensitive) • PSNHDD vs continuous outcome measures• PSNHDD vs abstinence outcome
![Page 21: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/21.jpg)
PSNHDD as Sensitive as Continuous Measures (COMBINE)
Naltrexone vs. Placebo
Measure Type Drinking Measure P Cohen d or h
continuous % heavy drinking days <0.01 .23
continuous drinks/day 0.02 .19
continuous drinks/drinking day 0.01 .21
continuous % days abstinent 0.01 .21
dichotomous PSNHDD <0.01 .22
dichotomous % subjects abstinent 0.06 .15
Outcomes measured during last two months of treatment
![Page 22: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/22.jpg)
Sensitivity of PSNHDD Depends on Grace Period
Grace period – a period in a trial where outcome is not considered in the analysis because the measured treatment effect is not thought to represent the full potential of the drug and the pattern of drinking is unstable
![Page 23: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/23.jpg)
Percent Subjects with Abstinence (PSA), Naltrexone vs. Placebo, COMBINE (Missing Data Imputed)
Cumulative Treatment Months - "Grace Periods"
1+2+3+4 2+3+4 3+4 40
20
40
60
80
100
20.525.2
31.1
38.4
17.7 19.7 24.327.2
Naltrexone Placebo
Treatment Month
h=.24*h=.07 h=.13 h=.15
PS
A (
%)
* p < 0.05
![Page 24: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/24.jpg)
Percent Subjects with No Heavy Drinking Days (PSNHDDs), Naltrexone vs. Placebo, COMBINE (Missing Data Imputed)
1+2+3+4 2+3+4 3+4 40
10
20
30
40
50
60
70
80
90
100
32.8
37.144.0
53.3
26.9 29.233.4
40.3
Cumulative Treatment Months - "Grace Periods"
Naltrexone (N=302) Placebo (N=305)
Treatment Months
PS
NH
DD
s (%
)
h=.13 h=.26**h=.22**h=.17*
![Page 25: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/25.jpg)
Percent Subjects with No Heavy Drinking Days (PSNHDDs), Naltrexone vs. Placebo, COMBINE (Missing Data Imputed)
1+2+3+4 2+3+4 3+4 40
10
20
30
40
50
60
70
80
90
100
32.8
37.144.0
53.3
26.9 29.233.4
40.3
Cumulative Treatment Months - "Grace Periods"
Naltrexone (N=302) Placebo (N=305)
Treatment Months
PS
NH
DD
s (%
)
h=.13 h=.26**h=.22**h=.17*
h=.07 h=.13 h=.15 h=.24*
![Page 26: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/26.jpg)
Varenicline Trial
• Duration: 3 months treatment
• Participants: alcohol dependent (n=198)
• At Randomization: no required abstinence
• Medications: varenicline vs placebo
• Results: – Varenicline significantly reduced many of continuous
drinking measures:
– Did not significantly reduce dichotomous measures
Litten et al. 2013. J Addict Med 7(4):277-86
![Page 27: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/27.jpg)
PSNHDD not as Sensitive as Continuous Measures Varenicline vs. Placebo
Measure Type Drinking Measure P Cohen d or h
continuous % heavy drinking days 0.01 .33
continuous drinks/day 0.02 .32
continuous drinks/drinking day 0.02 .29
continuous % days abstinent 0.20 .17
dichotomous PSNHDD 0.25 .10
dichotomous % subjects abstinence 0.68 .01
![Page 28: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/28.jpg)
Percent Subjects Abstinent – by Grace Period
PS
A
h=.01 h=.09 h=.12
Maintenance Period (Weeks 2-13)
Last 2 months Last Month0%
5%
10%
15%
20%
25%
30%
35%
2.0%
5.4%6.7%
2.1%
7.6%9.9%
Placebo Varenicline
all p>.05
![Page 29: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/29.jpg)
Percent Subjects with No Heavy Drinking Days – by Grace Period
PS
NH
DD
Maintenance Period (Weeks 2-13)
Last 2 months Last Month0%
5%
10%
15%
20%
25%
30%
35%
5.0%
11.8%
18.9%
7.3%
15.2%
27.5%
Placebo Varenicline
all p>.05
h=.10 h=.10 h=.20
![Page 30: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/30.jpg)
Percent Subjects with No Heavy Drinking Days – by Grace Period
PS
NH
DD
Maintenance Period (Weeks 2-13)
Last 2 months Last Month0%
5%
10%
15%
20%
25%
30%
35%
5.0%
11.8%
18.9%
7.3%
15.2%
27.5%
Placebo Varenicline
all p>.05
h=.10h=.01
h=.10h=.09
h=.20h=.12
![Page 31: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/31.jpg)
Summary
PSNHDD as an Endpoint• Not as sensitive as continuous
outcome measures
• Appears more sensitive than abstinence
• Need a grace period to show significance
![Page 32: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/32.jpg)
Will allowing additional heavy drinking days (HDD) improve
treatment effect?
![Page 33: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/33.jpg)
Cumulative Proportion of Responders Analysis
![Page 34: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/34.jpg)
Cumulative Proportion of Responder Analysis
Presents the proportion of responders over the entire range of possible cut-off points on a graph
Takes number of HDDs and creates all possible dichotomizations using different cut-offs (e.g, 0 HDD, <=1 HDD, <=2 HDD, etc)
![Page 35: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/35.jpg)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0
10
20
30
40
50
60
70
80
90
100
84 82 80 78 76 74 72 70 68 66 64 62 60 58 56 54 52 50 48 46 44 42 40 38 36 34 32 30 28 26 24 22 20 18 16 14 12 10 8 6 4 2 0
Treatment E
ffect (h)P
ropo
rtio
n of
Res
pond
ers
(%)
< X Heavy Drinking Days during Treatment
COMBINE Study (Months 2-4)
Placebo Naltrexone h
Treatment Effect Improves with More Lenient Outcomes….
Falk et al., J Stud Alcohol Drugs 75:335-346, 2014
![Page 36: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/36.jpg)
…yet Alcohol-Related Consequences increase with additional Heavy Drinking Days (more
lenient outcomes)
Falk et al. Alcohol Clin Exp Res 34:2022-2032, 20100 1 2 3 4 5 6 7-8 9-10 11-12 13-14 15-20 21-27 28-39 40-56
0
5
10
15
20
25
30
35
2.5
6.3
7.99.4 9.6 10.1
8.8
13.6
11.9
16.218.1
17.818.0
21.6
27.3
Number of Heavy Drinking Days
DrI
nC
To
tal
Sc
ore
(m
ea
n)
![Page 37: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/37.jpg)
What new analyses are being conducted to expand primary endpoints for Alcohol Clinical
Trials?
![Page 38: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/38.jpg)
New Analyses
Develop and validate more sensitive and clinically meaningful outcome measures Reduction of continuous drinking
outcomes Drinking categories of drinking
levels and patterns Non-drinking outcomes
![Page 39: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/39.jpg)
New Analyses
Data Sets of Different Alcohol Studies
• Rehm’s chronic disease• COMBINE, MATCH, NCIG trials• NESARC and other large
epidemiological surveys• Kaiser and other HMO
Research Networks
![Page 40: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/40.jpg)
Validation of Clinical Significance of Reduction in
Continuous Drinking Outcomes
Validate drinking against:
• alcohol-related consequences
• treatment utilization
• treatment cost
![Page 41: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/41.jpg)
Malignant Neoplasms
Source: Lim et al. 2012
![Page 42: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/42.jpg)
Rehm’s Chronic Disease DataDrinks per day (DPD): Varenicline = 4.4 vs. Placebo = 5.4 (Litten et al., 2013) • Is this ~ 1 DPD difference clinically meaningful?
Mouth and Oral Cancer
Placebo (RR=4.4)
Varenicline (RR= 3.5)
![Page 43: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/43.jpg)
Microsimulation Model to Estimate Clinical Relevance of Reducing Alcohol
ConsumptionNumber of Events per 100,000 Patients by Total Alcohol Consumption category per year
Francois, Rehm et al, Eur Addict Res 20:269-284, 2014
![Page 44: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/44.jpg)
Microsimulation Model to Estimate Clinical Relevance of Reducing Alcohol
Consumption
Number of Events per 100,000 Patients by HDDs per year
Francois, Rehm et al, Eur Addict Res 20:269-284, 2014
![Page 45: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/45.jpg)
Applying Microsimulation Model to Nalmafene Trial Outcomes
Difference between nalmefene and placebo groups
• ~1 drink/day = 692 fewer alcohol-attributable diseases and injuries/1000,000 alcohol dependent patients per year
• 3 heavy drinking days/month = 941 fewer
Francois, Rehm et al, Eur Addict Res 20:269-284
![Page 46: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/46.jpg)
Development of Risk Categories of Alcohol Intake
• Establish categories describing the risks/benefits at different levels and patterns of drinking
• Establish categories similar to clinical categories developed for blood pressure, cholesterol, and glycated hemoglobin
![Page 47: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/47.jpg)
Categories for Blood Pressure (BP)
BP Classification
Systolic BPmm Hg
Diastolic BPmm Hg
What to do
Normal <120 <80 Healthy lifestyle
Pre-Hypertension 120-139 80-89 Healthy lifestyle
Stage 1 Hypertension
140-159 90-99 Healthy lifestyle and medication
Stage 2Hypertension
>160 >99 Healthy lifestyle and medications
![Page 48: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/48.jpg)
Hypothetical Categories for Alcohol Consumption
Classification: Levels of Drinking
Cut-Off Values (based on risk/benefits associated with non-
drinking outcomes)Abstinence No drinking
Low-Risk DrinkingNot exceeds weekly limits (< 7/14 drinks/week for females/males) AND No heavy drinking days (HDDs)
Stage 1 (Low) High-Risk Drinking
Exceeds weekly (< 21/28 drinks/week) OR HDDs (up to 3x/month)
Stage 2 (Moderate)High-Risk Drinking
Exceeds weekly (< 49/56 drinks/week) ANDHDDs (up to 4x/week)
Stage 3 (Severe)High-Risk Drinking
Exceeds weekly (> 49/56 drinks/week) AND HDDs (daily or near daily/week)
Valuable information to stakeholders: regulatory agencies, pharmaceutical industry, researchers, patients, clinicians, and third-party payers
![Page 49: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/49.jpg)
WHO Risk Level
• World Health Organization’s gender-specific levels of risk• Standard drink = 14g = 0.6 oz of alcohol
Who Risk Level Definition
Abstinence Men: noneWomen: none
Low Men: 1-40g (<2.9 drinks)Women 1-20g (<1.4 drinks)
Medium Men: 40-60g (2.9-4.3 drinks)Women 20-40g (1.4-2.9 drinks)
High Men: 60-100g (4.3-7.1 drinks)Women 40-60g (2.9-4.3 drinks)
Very high Men: 100+g (7.1+ drinks)Women 60+g (4.3+ drinks)
![Page 50: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/50.jpg)
Develop and Validate Non-Drinking Outcomes
Validate Patient-Reported Outcomes (PRO) under FDA’s Clinical Outcome Assessments (COA):
• Alcohol-Related Consequences: Lilly started validation of DRINC, resulting in 15-item measure (IMBIBE)
• Craving: not yet started
![Page 51: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/51.jpg)
IMBIBE
![Page 52: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/52.jpg)
52
Placebo 12.5 HDDVarenicline
8.5 HDD
![Page 53: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/53.jpg)
53
“IMBIBE items sensitive to HDDs”
![Page 54: Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD Raye Z. Litten, Ph.D. Daniel Falk, Ph.D. (Discussant) Division of Treatment and Recovery.](https://reader035.fdocuments.in/reader035/viewer/2022081519/56649da15503460f94a8d2f7/html5/thumbnails/54.jpg)
Summary and Conclusions
• Progress in developing and evaluating new sensitive and clinically relevant alcohol outcomes
– reduction in drinking for continuous outcomes
– categories of drinking levels and patterns
– non-drinking outcomes
• New approaches during next decade
N